Mitigation of Radiation Injury via Vascular Regeneration and Remodeling

加州大学洛杉矶分校-CMCR项目的主题是发现和 开发新的和独特的药物，或重新调整现有药物的用途，以缓解急性、延迟和 长期辐射综合症。我们已经确定了30多种造血急性期的缓解剂 辐射综合征(H-ARS)，其中一些处于相当高级的药物开发阶段。有些是 对急性、延迟和长期辐射组织损伤的多种模型有效，这使得 它们特别令人感兴趣，因为人体内的每个细胞在暴露于中等剂量的 通过放射治疗和多种药物治疗来缓解每一种综合症几乎是不可能的。我们 相信广泛的活动是通过原始的、高度保守的、发展的行动产生的 负责身体结构形成的信号通路，但也引导 促进受损组织的再生，调节慢性炎症。这些通路在细胞周期中的作用 不同的辐射综合征，急性的和延迟的，形成了这一应用的主要主题。我们的项目 因此，将扩展我们的缓释剂产品组合，重点放在发育信号通路上 在多个组织中。两个侧重于急性综合征，两个侧重于晚期综合征。我们相信 急性辐射暴露(DEARE)的延迟效应是由于在H-ARS期间未完全愈合， 导致免疫系统扭曲，产生持续的氧化应激，慢性 炎症，以及多个组织中的动态平衡失调。这与我们的发现是一致的 通过触发发育通路信号转导的药物缓解H-ARS可以影响DEARE。我们的 服务核心面向药物和动物模型优化。它们将提高疗效，并 通过FDA批准的配方和化学合成提供药物，旨在改善 物质的溶解度、药代动力学、作用机制和唯一性。动物模型将会 具有病理生理学定义的急性和延迟终点的剂量-反应关系 使用诺生菌和无菌小鼠品系的发病率和死亡率。我们将进行比较， FDA批准的H-ARS缓释剂在这些不同的辐射综合征中的作用。这个 管理核心用于集成项目、服务核心和试点项目，并提供 作为联系中华儿科研究中心、政府机构、工业界和学术界的渠道。它提供了凝聚力， UCLA-CMCR，并确保其满足NIAID、FDA和 中国移动通信股份有限公司。它还为成员提供教育基础设施，其执行委员会提供帮助 调查人员将药物优先用于开发和测试，并具有监管和知识产权 问题。

The theme of the UCLA-CMCR Program is to discover and develop novel and unique drugs, or to repurpose existing agents, that mitigate acute, delayed, and long-term radiation syndromes. We have already identified over 30 mitigators of hematopoietic acute radiation syndrome (H- ARS), some of which are in quite advanced drug development. Some are effective in multiple models of acute, delayed and long-term radiation tissue damage, which makes them of particular interest as every cell in the body is damaged after exposure to moderate doses of radiation and polypharmacy to mitigate every syndrome would be almost impossible to achieve. We believe that broad activity results from action through primitive, highly conserved, developmental signaling pathways that are responsible for the formation of body structures, but that also guide regeneration in damaged tissues and regulate chronic inflammation. The role of these pathways in diverse radiation syndromes, acute and delayed, form a major theme in this application. Our Projects will therefore extend our portfolio of mitigators with an emphasis on developmental signaling pathways in multiple tissues. Two focus on Acute syndromes and two on late syndromes. We believe that delayed effects of acute radiation exposure (DEARE) are due to incomplete healing during H-ARS, resulting in skewing of the immune system that generates persistent oxidative stress, chronic inflammation, and dysregulated homeostasis in multiple tissues. This is consistent with our finding that mitigation of H-ARS by drugs that trigger developmental pathway signaling can affect DEARE. Our Service Cores are geared to drug and animal model optimization. They will improve the efficacy and delivery of drugs through FDA-approved formulation and chemical synthesis that aims to improve solubility, pharmacokinetics, mechanisms of action, and uniqueness of matter. The animal models will have pathophysiologically-defined, dose-response relationships for acute and delayed endpoints of morbidity and mortality using gnotobiotic and germ-free mouse strains. Comparisons will be made to the effects of FDA-approved H-ARS mitigators in these diverse radiation syndromes. The Administrative Core serves to integrate projects, service cores, and pilot projects and provides a conduit to the CMCRC, governmental bodies, industry, and academia. It provides cohesion for the UCLA-CMCR and ensures that it meets the common goals established by NIAID, the FDA, and the CMCRC. It also provides an educational infrastructure for members and its Executive Committee helps investigators prioritize drugs for development and testing, and with regulatory and intellectual property issues.